- Report
- March 2025
- 187 Pages
Global
From €3371EUR$3,545USD£2,834GBP
€3745EUR$3,939USD£3,149GBP
- Report
- October 2024
- 192 Pages
Global
From €3371EUR$3,545USD£2,834GBP
€3745EUR$3,939USD£3,149GBP
- Report
- August 2024
- 100 Pages
Global
From €5657EUR$5,950USD£4,757GBP
- Report
- March 2025
- 380 Pages
Global
From €5182EUR$5,450USD£4,357GBP
- Report
- February 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- January 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- March 2025
- 150 Pages
Global
From €4611EUR$4,850USD£3,878GBP
- Report
- May 2024
- 136 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- May 2024
- 131 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Clinical Trials
- July 2024
- 80 Pages
Global
From €1902EUR$2,000USD£1,599GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1189EUR$1,250USD£999GBP
- Report
- May 2024
- 160 Pages
Global
From €4725EUR$4,969USD£3,973GBP
- Report
- July 2024
Global
From €4611EUR$4,850USD£3,878GBP
- Report
- May 2023
- 160 Pages
Global
From €4706EUR$4,949USD£3,957GBP
- Report
- April 2023
- 147 Pages
Global
From €4706EUR$4,949USD£3,957GBP
- Report
- March 2023
- 147 Pages
Global
From €4706EUR$4,949USD£3,957GBP
- Report
- November 2023
- 161 Pages
Global
From €2377EUR$2,500USD£1,999GBP
- Drug Pipelines
- September 2020
- 737 Pages
Global
From €2377EUR$2,500USD£1,999GBP
- Report
- March 2024
- 132 Pages
Middle East, Africa
From €1426EUR$1,500USD£1,199GBP

Mood stabilizers are a class of drugs used to treat mental disorders, such as bipolar disorder, depression, and anxiety. These drugs work by regulating the levels of neurotransmitters in the brain, which can help to reduce the intensity of mood swings and other symptoms associated with mental disorders. Commonly prescribed mood stabilizers include lithium, valproic acid, carbamazepine, and lamotrigine.
Mood stabilizers are an important part of the mental disorders drugs market, as they can help to reduce the severity of symptoms and improve quality of life for those affected. They are often used in combination with other medications, such as antidepressants, to provide a comprehensive treatment plan.
Some of the companies in the mood stabilizer market include AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more